Adherence to Growth Hormone Treatment Using a Connected Device in Latin America: Real-World Exploratory Descriptive Analysis Study

Aria Assefi¹, MD; Paula van Dommelen², PhD; Lilian Arnaud³, MSc; Carlos Otero⁴, MD; Luis Fernandez-Luque⁵, PhD; Ekaterina Koledova⁶, MD, PhD; Luis Eduardo Calliari⁷, MD

¹Fertility and Endocrinology, Merck SA (an affiliate of Merck KGaA, Darmstadt, Germany), Buenos Aires, Argentina
²Department of Child Health, The Netherlands Organization for Applied Scientific Research TNO, Leiden, Netherlands
³Global Healthcare Operations, Connected Health & Devices, Ares Trading SA (an affiliate of Merck KGaA, Darmstadt, Germany), Eysins, Switzerland
⁴Departamento de Informática en Salud, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina
⁵Adhera Health Inc, Palo Alto, CA, United States
⁶Global Medical Affairs Cardiometabolic & Endocrinology, the healthcare business of Merck KGaA, Darmstadt, Germany
⁷Pediatric Endocrinology Unit, Pediatric Department, Santa Casa de São Paulo School of Medical Sciences, São Paulo, Brazil

Corresponding Author:
Aria Assefi, MD
Fertility and Endocrinology
Merck SA (an affiliate of Merck KGaA, Darmstadt, Germany)
Edificio Panamericana Plaza
Tronador
Buenos Aires, 4890
Argentina
Phone: 54 9 11 2275146
Email: aria.assefi@merckgroup.com

Abstract

Background: Recombinant human growth hormone (rhGH) therapy is an effective treatment for children with growth disorders. However, poor outcomes are often associated with suboptimal adherence to treatment.

Objective: The easypod connected injection device records and transmits injection settings and dose data from patients receiving rhGH. In this study, we evaluated adherence to rhGH treatment, and associated growth outcomes, in Latin American patients.

Methods: Adherence and growth data from patients aged 2-18 years from 12 Latin American countries were analyzed. Adherence data were available for 6207 patients with 2,449,879 injections, and growth data were available for 497 patients with 2232 measurements. Adherence was categorized, based on milligrams of rhGH injected versus milligrams of rhGH prescribed, as high (≥85%), intermediate (>56%-<85%), or low (≤56%). Transmission frequency was categorized as high (≥1 per 3 months) or low (<1 per 3 months). Chi-square tests were applied to study the effect of pubertal status at treatment start and sex on high adherence, and to test differences in frequency transmission between the three adherence levels. Multilevel linear regression techniques were applied to study the effect of adherence on observed change in height standard deviation score (ΔHSDS).

Results: Overall, 68% (4213/6207), 25% (n=1574), and 7% (n=420) of patients had high, intermediate, and low adherence, respectively. Pubertal status at treatment start and sex did not have a significant effect on high adherence. Significant differences were found in the proportion of patients with high transmission frequency between high (≥1 per 3 months) and low (<1 per 3 months). Mean catch-up growth between 0-24 months was +0.65 SD overall (+0.52 SD in patients with low/intermediate monthly adherence and +0.69 SD in patients with high monthly adherence). This difference translated into 1.1 cm greater catch-up growth with high adherence.

Conclusions: The data extracted from the easypod Connect ecosystem showed high adherence to rhGH treatment in Latin American patients, with positive growth outcomes, indicating the importance of connected device solutions for rhGH treatment in patients with growth disorders.
Introduction

Adherence to long-term pharmacological treatments, such as growth hormone (GH) therapy for growth disorders, is an area with great potential for improvement [1,2]. Poor long-term adherence to GH treatment is known to affect final adult height and additional clinical outcomes in children with growth disorders [3]. Moreover, enthusiasm and motivation to adhere to treatment may decrease over time because the long-term benefits of GH treatment are not immediately obvious to children, and administering daily subcutaneous injections places a significant burden on them and their parents/caregivers [3-5]. Indeed, adherence to GH treatment has been shown to be statistically significantly higher in treatment-naive children compared with those experienced in their treatment [4].

Adherence to GH treatment in the real-world setting has always been difficult to monitor, given the use of unreliable proxy methods such as patient testimony or records of prescriptions filled/vials counted [4,5]. Furthermore, detection of poor adherence to GH treatment can be problematic because patients/caregivers may be reluctant to admit to (or do not remember) missed doses and may overestimate their adherence to treatment during discussions with health care providers (HCPs) [4]. Devices that offer a dose-setting memory may therefore be beneficial in improving adherence [6]. In addition, with prevalence estimates of nonadherence ranging from 5% to 82% [5], it is difficult to compare adherence rates among studies due to the variability in methods used to evaluate and define adherence [5,7]. Lastly, studies assessing adherence are sometimes constrained by low patient numbers and there is often only one participating center, which limits the extrapolation of results to different settings [8].

Automatic transmission of injection data provides a more accurate insight into real-world adherence patterns and enables HCPs to potentially eliminate poor adherence as a reason for a suboptimal response to GH treatment [4,9,10]. The use of a connected injection device to deliver GH treatment limits the risk of misreporting or faulty recall of adherence, and allows HCPs to accurately monitor their patients’ real-world adherence behavior over time [9]. Patient confidentiality is maintained because only the treating HCPs and patient support programs (PSPs) can access patients’ complete data from a secure cloud-based database, and only deidentified (pseudonymized) data are used to generate aggregated and anonymized results for research purposes. A connected injection device thereby enables HCPs to access the transmitted data and gain insights into both individual and overall patterns of adherence to GH treatment [9,11].

As different health care systems and variations in clinical practice around the world may affect adherence locally, the deployment of a connected injection device for the treatment of growth disorders across different countries allows the study of behavioral adherence patterns across populations and longitudinally for thousands of patients. This substantial compendium of patient-generated data has also been applied in the context of understanding patterns in diabetes thanks to glucose monitoring technologies [12,13]. In terms of monitoring adherence in large cohorts, oral medication use has been monitored using “smart pillboxes” [14] and “smart pill bottles” [15,16].

Global analysis of real-world data obtained from connected injection devices for GH treatment has shown that children with high adherence were most likely to regularly transmit data, and that prepubertal children showed higher adherence than older children and adolescents [17]. This analysis showed the potential of developing a global adherence decision support system (ADSS) by analyzing trends in real-world adherence data, but did not include insights from different health care systems.

The Latin American region is one of the fastest growing regions in terms of the adoption of digital health [18,19]. This has facilitated the implementation of a web-based platform connected with injection devices for GH treatment across several countries in Latin America, a region in which digital health studies have previously been lacking. The objective of this study, therefore, was to evaluate real-world adherence to recombinant human GH (rhGH) therapy administered via a connected injection device in one specific region (Latin America) to provide an update to an earlier, smaller Latin American analysis, previously published only in abstract form [11]. Additionally, we studied catch-up growth and its association with adherence in a subgroup of patients.

Methods

Patient Population

In this analysis, we included children with growth disorders from 12 Latin American countries (Argentina, Brazil, Chile, Colombia, Costa Rica, Dominican Republic, El Salvador, Guatemala, Mexico, Nicaragua, Panama, and Peru) and assessed the effects of pubertal status at treatment start, sex, and engagement with treatment on their adherence. An analysis of longitudinal records for a total of 13,553 children in the global database was recently published [17], but here we focus only on data from patients in these Latin American countries. The total data set available in the global database comprises data from the 5-year global Easypod Connect Observational Study (ECOS) [9] and from all patients worldwide who have received treatment with rhGH (somatropin [Saizen]; the healthcare business of Merck Healthcare KGaA, Darmstadt, Germany) administered via the easypod connected injection device.
A Digital Ecosystem for Supporting and Monitoring Adherence to rhGH Therapy

The easypod electromechanical injection device, in combination with the easypod Connect web-based platform, as part of an ADSS [20], electronically records accurate, objective details of the date, time, and dose of injections for patients receiving rhGH for the treatment of growth disorders [21]. All of these data are recorded by the device and stored internally for up to 3 years. The patient can then transmit these data to the easypod Connect platform and a secure internet cloud-based database [9].

Study Design and Inclusion Criteria

This was an exploratory descriptive analysis study during which 4 years of adherence data were analyzed from 6207 pediatric patients with 2,449,879 prescribed injections of rhGH delivered via easypod to treat growth disorders, and who were transmitting data to the easypod Connect system between January 2007 and December 2020. These patients resided in 12 Latin American countries (Figure 1). To avoid inclusion of test doses or training injections, only data after the 10th injection registered for each individual were analyzed. Data were downloaded from the easypod Connect platform in January 2021, but the period of recorded data varied according to each individual patient’s treatment duration. Transmission data from January 2016 to December 2020 were used. We selected patients who were aged 2-18 years at treatment start.

Eligible patients from each of the participating countries had been enrolled in the database and attended at least one visit, according to local routine clinical practice. Diagnoses and decisions on treatment were made at the discretion of the physician responsible for each patient, following standard endocrinologic practice for each of the participating countries. Prior to enrollment, patients/caregivers reviewed and voluntarily signed an informed consent form materializing their agreement for data collection, storage, and use of their child’s pseudonymized data to create aggregated statistical and general adherence reports.

Figure 1. Participating Latin American countries.

For height, we selected patients with at least two measurements. Adherence (calculated as milligrams of rhGH injected versus milligrams of rhGH prescribed) was categorized as high (≥85%), intermediate (>56%-<85%), or low (≤56%) for patients on either 6 or 7 injections per week, the two possible regimens for treatment with rhGH. The dosage and frequency of rhGH therapy as per easypod settings were defined by HCPs and data transmissions were initiated by the child, parent/caregiver, or HCP. Adherence was assessed overall and monthly, and explored by puberty status at treatment start (nominal cutoffs at 10 years for girls, and 12 years for boys), sex, and transmission frequency (defined as the total number of transmissions divided by the duration of treatment, and categorized as high [≥1 per 3 months] versus low [<1 per 3 months]) in the selected patients with available adherence data for ≥3 months between January 2016 and December 2020.
Transmission frequency was calculated in each adherence category as a proxy measure of the patient’s engagement in disease management using easypod. No imputation was made for missing data or withdrawal from the study.

**Patient Data and Calculations**

Height data were available for 497 patients with 2232 measurements; this included 355 patients from Argentina, 64 from Brazil, 70 from Guatemala, and 8 from Mexico. Height standard deviation scores (HSDS) were calculated using the World Health Organization references [22,23]. Linear interpolation between height measurements was applied to calculate monthly catch-up growth (ΔHSDS) overall, and by low/intermediate versus high adherence, and within the subgroup of patients (n=40) aged <8 years with HSDDS of ≤−2, for which we assume an optimal catch-up growth. The cutoff of 8 years was chosen so the definition of short stature, age, and treatment duration ensured this would be before the start of puberty in both genders. Cubic smoothing splines were fitted to obtain the curves for catch-up growth between 0-24 months.

**Statistical Analysis**

Descriptive statistics were used to describe differences over time in adherence (low, intermediate, or high), puberty status (prepubertal or pubertal), and sex. Chi-square tests were applied to test differences in adherence between girls and boys, and between prepubertal and pubertal girls and boys. In addition, a Chi-square test was applied to test differences in high frequency transmission between the high, intermediate, and low adherence groups. Multilevel linear regression techniques were applied to study the effect of adherence level on ΔHSDS between all observed growth measurements, adjusted for the time intervals between them.

**Ethical Considerations**

Treatment with rhGH via easypod was conducted according to local practice. This real-world, retrospective analysis of the data set was performed in accordance with the informed consent form, signed by caregivers of children and adult patients materializing their agreement for data collection, storage, and use of their pseudonymized data to create aggregated statistical and general adherence reports.

**Data Availability Statement**

Any requests for data by qualified scientific and medical researchers for legitimate research purposes will be subject to the healthcare business of Merck KGaA’s Data Sharing Policy. All requests should be submitted in writing to the healthcare business of Merck KGaA’s data sharing portal [24]. When the healthcare business of Merck KGaA has a coresearch, codevelopment, or co-marketing or comarketing agreement, or when the product has been outlicensed, the responsibility for disclosure might be dependent on the agreement between parties. Under these circumstances, the healthcare business of Merck KGaA will endeavor to gain agreement to share data in response to requests.

**Results**

**Patient Population and Demographics**

Complete data were available for 6207 patients, where “overall” is defined here (and throughout) as the total number of patients who received rhGH, started treatment at age 2-18 years, and for whom data were available. Transmission data were available for 5086 patients. Patient demographics according to adherence rates are presented for this data set in Table 1. The number of patients decreased from 6207 patients in the first month (100%), to 3594 patients (58%) at month 12, to 1707 patients at month 24, and to <600 patients (<10%) after month 36 (Figure 2; black line). Growth data were available for 497 patients overall, and decreased to 330 patients at months 13-24, 150 patients at months 25-36, and 37 patients at months 37-48.

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>Adherence</th>
<th>Total (N=6207)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>High (n=4213)</td>
<td>Intermediate (n=1574)</td>
</tr>
<tr>
<td>Mean age (SD) of boys at start, years</td>
<td>10.6 (3.4)</td>
<td>10.9 (3.3)</td>
</tr>
<tr>
<td>Boys aged &lt;12 years at start, n (%)</td>
<td>1424 (68)</td>
<td>526 (25)</td>
</tr>
<tr>
<td>Boys aged ≥12 years at start, n (%)</td>
<td>985 (66)</td>
<td>394 (26)</td>
</tr>
<tr>
<td>Mean age (SD) of girls at start, years</td>
<td>9.7 (2.8)</td>
<td>10.0 (2.8)</td>
</tr>
<tr>
<td>Girls aged &lt;10 years at start, n (%)</td>
<td>839 (69)</td>
<td>308 (25)</td>
</tr>
<tr>
<td>Girls aged ≥10 years at start, n (%)</td>
<td>965 (69)</td>
<td>346 (25)</td>
</tr>
</tbody>
</table>

*a Adherence was categorized as high (≥85%), intermediate (>56%<85%), or low (<56%).
Figure 2. Proportion of patients who were adherent at each time point. Adherence was recorded for the cross-section of children or their caregivers transmitting data at each time point; no imputation was made for missing data or withdrawal from the study.

Adherence Overall and Over Time
Overall, 68% (4213/6207) of patients were in the high adherence category, 25% (n=1574) were in the intermediate adherence category, and 7% (n=420) were in the low adherence category. Furthermore, at each time point, there was a higher proportion of patients in the high adherence category than in the intermediate and low categories combined (Figure 2). High adherence decreased from 89% (5514/6207) to 59% (1013/1707) between 1-24 months, and ranged from 50%-62% between 25-48 months. However, despite there being a decrease in the proportion of patients in the high adherence category over time, 67% (2399/3594) and 59% (1013/1707) of patients were still in the high adherence category at months 12 and 24, respectively.

Effect of Age, Sex, and Engagement With the Easypod Device on Adherence
There were no significant differences in high adherence between boys (2409/3598, 67%) and girls (1804/2609, 69%) or between prepubertal and pubertal patients (1424/2107, 68% versus 985/1491, 66% in boys, both 69% [839/1219; 965/1390] in girls, respectively). Figures 3A and 3B show adherence at each time point stratified by nominal pubertal age and sex. Figure 3A shows a larger proportion of prepubertal boys with high adherence between 1-25 months compared with pubertal boys. For the majority of these months (17/25), the proportion of high adherence was significantly (P<.05) higher in prepubertal boys compared with pubertal boys.
Figure 3. Adherence at each time point stratified by nominal pubertal age and sex (A: boys, B: girls). Adherence was recorded for the cross-section of children or their caregivers transmitting data at each time point; no imputation was made for missing data or withdrawal from the study.

In addition, there were significant differences in the proportion of patients with high transmission frequency between the adherence groups; 59% (2018/3404), 46% (608/1331), and 35% (123/351) in the high, intermediate, and low adherence groups, respectively ($P<.001$).

Between-Country Variation

The proportion of children in the high adherence category varied by country, ranging from 45% (10/22) in the Dominican Republic to 82% (943/1144) in Brazil (Table 2).
## Table 2. Adherence rates by age, sex, and country.

<table>
<thead>
<tr>
<th>Country and adherence&lt;sup&gt;a&lt;/sup&gt;</th>
<th>Boys aged &lt;12 years, n</th>
<th>Boys aged ≥12 years, n</th>
<th>Girls aged &lt;10 years, n</th>
<th>Girls aged ≥10 years, n</th>
<th>Total number of patients with ≥1 injection</th>
<th>Adherence ≥85%, n (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Argentina</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>1147</td>
<td>759 (66)</td>
</tr>
<tr>
<td>High</td>
<td>322</td>
<td>163</td>
<td>151</td>
<td>123</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Intermediate</td>
<td>113</td>
<td>72</td>
<td>66</td>
<td>41</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Low</td>
<td>46</td>
<td>19</td>
<td>18</td>
<td>13</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Brazil</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>1144</td>
<td>943 (82)</td>
</tr>
<tr>
<td>High</td>
<td>347</td>
<td>225</td>
<td>169</td>
<td>202</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Intermediate</td>
<td>68</td>
<td>39</td>
<td>35</td>
<td>35</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Low</td>
<td>9</td>
<td>3</td>
<td>6</td>
<td>6</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Chile</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>1344</td>
<td>949 (71)</td>
</tr>
<tr>
<td>High</td>
<td>291</td>
<td>242</td>
<td>176</td>
<td>240</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Intermediate</td>
<td>96</td>
<td>84</td>
<td>44</td>
<td>95</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Low</td>
<td>17</td>
<td>33</td>
<td>12</td>
<td>14</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Colombia</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>1122</td>
<td>625 (56)</td>
</tr>
<tr>
<td>High</td>
<td>170</td>
<td>152</td>
<td>149</td>
<td>154</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Intermediate</td>
<td>125</td>
<td>108</td>
<td>81</td>
<td>86</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Low</td>
<td>39</td>
<td>22</td>
<td>18</td>
<td>18</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Costa Rica</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>10</td>
<td>8 (80)</td>
</tr>
<tr>
<td>High</td>
<td>4</td>
<td>3</td>
<td>0</td>
<td>1</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Intermediate</td>
<td>0</td>
<td>1</td>
<td>1</td>
<td>0</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Low</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Dominican Republic</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>22</td>
<td>10 (45)</td>
</tr>
<tr>
<td>High</td>
<td>1</td>
<td>3</td>
<td>3</td>
<td>3</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Intermediate</td>
<td>2</td>
<td>0</td>
<td>0</td>
<td>4</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Low</td>
<td>2</td>
<td>3</td>
<td>0</td>
<td>1</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>El Salvador</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>50</td>
<td>27 (54)</td>
</tr>
<tr>
<td>High</td>
<td>7</td>
<td>12</td>
<td>5</td>
<td>3</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Intermediate</td>
<td>8</td>
<td>5</td>
<td>2</td>
<td>3</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Low</td>
<td>1</td>
<td>1</td>
<td>2</td>
<td>1</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Guatemala</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>321</td>
<td>221 (69)</td>
</tr>
<tr>
<td>High</td>
<td>71</td>
<td>38</td>
<td>43</td>
<td>69</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Intermediate</td>
<td>26</td>
<td>14</td>
<td>18</td>
<td>16</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Low</td>
<td>8</td>
<td>12</td>
<td>0</td>
<td>6</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Mexico</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>554</td>
<td>355 (64)</td>
</tr>
<tr>
<td>High</td>
<td>113</td>
<td>83</td>
<td>72</td>
<td>87</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Intermediate</td>
<td>48</td>
<td>40</td>
<td>32</td>
<td>33</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Low</td>
<td>23</td>
<td>9</td>
<td>6</td>
<td>8</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Nicaragua</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>68</td>
<td>33 (49)</td>
</tr>
<tr>
<td>High</td>
<td>13</td>
<td>8</td>
<td>5</td>
<td>7</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Intermediate</td>
<td>8</td>
<td>7</td>
<td>5</td>
<td>4</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Low</td>
<td>6</td>
<td>1</td>
<td>2</td>
<td>2</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Panama</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>43</td>
<td>23 (53)</td>
</tr>
</tbody>
</table>
Country and adherence\(^a\) & Boys aged <12 years, n & Boys aged ≥12 years, n & Girls aged <10 years, n & Girls aged ≥10 years, n & Total number of patients with ≥1 injection & Adherence ≥85%, n (%) \\
--- & --- & --- & --- & --- & --- & --- \\
High & 6 & 5 & 4 & 8 & & \\
Intermediate & 5 & 3 & 3 & 6 & & \\
Low & 2 & 1 & 0 & 0 & & \\
Peru & & & & & 382 & 260 (68) \\
High & 79 & 51 & 62 & 68 & & \\
Intermediate & 27 & 21 & 21 & 23 & & \\
Low & 4 & 8 & 8 & 10 & & \\

\(^a\) Adherence was categorized as high (≥85%), intermediate (>56%-<85%), or low (≤56%).

**Catch-up Growth**

Figure 4 shows the mean catch-up growth (ΔHSDS) between 0-24 months, stratified by high versus intermediate/low adherence. Adherence level (low/intermediate versus high) had a significant effect on ΔHSDS (\(P=0.006\)). Mean catch-up growth between 0-12 months was +0.39 SD overall, with +0.27 SD in patients with low/intermediate monthly adherence and +0.42 SD in patients with high monthly adherence. Mean catch-up growth between 0-24 months was +0.65 SD overall, with +0.52 SD in patients with low/intermediate monthly adherence and +0.69 SD in patients with high monthly adherence. Mean catch-up growth within the subgroup of patients (n=40) aged <8 years and HSDS <–2 at start was +1.03 SD. It was not possible to stratify this subgroup of patients by low and high adherence due to the small sample size.

Figure 4. Catch-up growth between 0-24 months stratified by low/intermediate adherence (<85%) and high adherence (≥85%). ΔHSDS: change in height standard deviation score.
Discussion

Principal Results
The data extracted from the easypod Connect ecosystem showed that children receiving rhGH therapy demonstrated high adherence over 4 years in a real-world setting in 12 Latin American countries.

Use of easypod Connect, which showed high adherence in patients with high transmission rates, could be regarded as a proxy of usability and utility of the system by patients and HCPs. In such large-scale deployments of digital health systems, usability cannot be easily measured using questionnaires as this would pose a major user/participant burden. Instead, transmissions and data usage can be used toward identifying patterns of usage of the system and adherence to treatment. Indeed, in this regard, a framework has been proposed to guide future implementation and research on the use of digital health tools to support patients with growth disorders who require GH therapy [25]. These insights can be further investigated in smaller-scale studies (eg, exploring qualitative issues with interviews).

We observed that patients who transmitted their data tended to have higher adherence; therefore, a potential hypothesis to further explore is the impact of patients knowing that their adherence data is being observed and is useful to their HCP. Studies in other therapeutic areas have found that factors related to the Theory of Planned Behavior can predict ~50% variance in adherence [26]. Future studies can look into the behavioral impact of monitoring adherence and the role this plays in the interaction of HCPs with the data during clinical visits (eg, clinicians reviewing adherence data during the patient visit, how the system is introduced to the patient).

Comparison With Other Studies
The selected data from this regional study are broadly consistent with recently published data from the global easypod Connect database, which demonstrated that, of 13,553 children, 71% were in the high adherence category [17], and with a previous exploratory analysis (68% in the high adherence category) [27]. Children with high adherence were most likely to regularly transmit data, reflecting engagement with the easypod device [17]. Furthermore, the ECOS has shown that the majority (62%) of patients maintained an observed adherence rate of ≥80% to rhGH therapy over 3 years of easypod use [9]. Similarly, a preliminary analysis evaluated real-world adherence to rhGH therapy administered via easypod over 1, 3, 6, and 12 months in Latin American patients [11]. Analysis of data extracted in February 2018 from 2727 patients transmitting their injection data to easypod Connect showed that the majority (67%) were still in the high adherence category (defined as ≥85%) at 12 months, with girls (64% versus 63% of boys) and prepubertal patients (69% versus 60% of pubertal patients) being the most adherent [11].

In both the preliminary Latin American study and other analyses, the proportion of children with high adherence declined over time, and factors such as sex and nominal age at puberty appeared to have only a small effect on adherence rates [11,17]. Similarly, in this study, after 12 months, 33% (n=1195 out of N=3594) of Latin American patients were in the low or intermediate adherence categories, while this was 11% (n=693 out of N=6207) in the first month of treatment. Additionally, a slightly higher proportion of girls overall were in the high adherence category compared with boys, as were patients who were prepubertal at treatment start versus pubertal patients; however, overall, these results were not statistically significant. These results demonstrate that adherence is an issue that needs to be addressed continuously by HCPs and included in discussions with patients and their families/caregivers, taking both patient sex and pubertal status into account.

Patient attrition over time may be due to a number of factors. Patients may have been switched to a different rhGH, may have continued taking somatropin rhGH using a pen injector, may have continued taking rhGH using easypod but without performing any further data transmission, or may have stopped treatment completely. Minimizing patient attrition is an important consideration in long-term clinical trials, and determining the predictors of attrition is key to identifying patients at risk of missed visits or dropout; such patients may be excluded from a trial or efforts may need to be made to prevent their subsequent dropout once enrolled [28]. This is especially important in the case of growth disorders since rhGH treatment is required over the long term and requires good adherence to achieve optimal outcomes. Indeed, determining predictors of attrition and using early trial retention strategies (eg, management of reluctant or hard-to-locate study participants) have led to improved attrition rates in studies of asthma and behavioral disorders [28,29]. Thus, such approaches could be considered in future studies investigating adherence to rhGH treatment.

Indeed, previously reported individual cases of patients receiving rhGH have indicated that direct access to adherence monitoring by HCPs followed by intervention can make a difference to a patient’s management and motivation [30-32]. The authors’ personal experience shows that, in many cases, families are not always aware that their child’s adherence is suboptimal and are surprised by this information when informed by the HCP of the data recorded by easypod. This information is key because it can explain a smaller growth catch-up without the need for further investigation into other potential causes. In this regard, devices with a dose setting were the preferred choice among patients and caregivers in a recent study by Tanaka et al [6].

Optimizing adherence might also be achieved through the use of structured and active interventions from HCPs, patient/caregiver support programs [33], and/or digital interventions to help manage adherence over the long-term course of rhGH treatment. Although extensive evidence is available in the adult population [34-36], there are few studies addressing the unique needs of digital adherence support in pediatrics [37]. However, the potential of gamified interventions to promote and improve adherence in pediatric patients has recently been demonstrated [38].

Strengths and Limitations
The strengths of our study include the large data set from a real-world study conducted across 12 countries in one
geographic region with substantially diverse and dynamic health care systems, and the fact that the data are derived from a connected injection device, which offers more reliable data compared to data based on the declarations of patients or their parents/caregivers. Comparable insights into patient adherence from other large-scale patient registries for rhGH treatment are not available due to the lack of alternative electronic devices similar to easypod.

Further work is required to assess whether patient/caregiver engagement, as measured by the rate and frequency of data transmission with easypod, is associated with better long-term adherence and clinical outcomes for patients. It would also be interesting to investigate whether or not there is a correlation between the frequency of dose adjustments and the adherence/transmission rate.

Limitations of the study include patient attrition, summarized above, and the fact that the change in adherence rate over time varied from child to child, perhaps due to changes in individual treatment plans or other actions taken by the HCP or child/family. Furthermore, not all data were available for all patients over the same treatment duration, as would be expected in any observational study. Differences between the 12 participating countries in terms of socioeconomic factors, such as reimbursement and/or out-of-pocket expenses for GH therapy or free access to medication, may also have affected individual or local adherence rates. Similarly, differences in prescribing habits (eg, prescription provided for 1, 2, 3, or 6 months), patients’ visits to the clinic where growth response is checked and dose might be adjusted to maximize response to treatment, and refill of prescriptions from country to country may also affect adherence rates. Other potential limitations include the lack of additional information on diagnosis and clinical background, limited data on growth outcomes that do not allow assessment of the full catch-up growth pattern, and lack of patient-reported data such as reasons for discontinuation or interruption of treatment, or predefined actions taken by PSPs [39] in the various countries involved. These data might have been available through linkage to electronic health records (EHRs) where this is permitted, or by allowing patients to have self-reported outcomes entered separately into the system via an app.

Finally, usage of the system (ie, adherence and transmission rates) can be a proxy of usability and utility; however, usage has been to a large extent influenced by the way the system was introduced. All of these areas require more research. Our analysis showed less catch-up growth (–0.17 SD over 24 months) in patients who continue to have low/intermediate adherence compared with patients with high adherence, and this difference increased over time. This difference could be translated into centimeters, resulting in 1.1 cm less catch-up growth between 0-24 months for a patient with an average age for the group (10 years). This is in agreement with the literature, which shows that greater adherence leads to improved growth, with poor adherence adversely affecting growth outcomes [9,10,40]. In the ECOS analyses, statistically significant correlations were observed between adherence and 1-year ΔHSDS (P <.001 for patients overall) and height velocity (P <.001) [9].

Future Work

In terms of future research opportunities, analysis of the potential differences between countries with preset additional data collection points would be of interest. The value of this data can be enhanced by complementing it with self-reported height data entered via a patient app. Future research may also allow for automatic self-measurement of height using novel augmented reality technology on mobile phones. Finally, integration with EHRs may facilitate clinical workflows, as has been demonstrated in other therapy areas [16].

Conclusions

Analysis of the data extracted from easypod Connect showed high adherence to rhGH treatment in Latin American patients, with positive growth outcomes. Thus, our study indicates the potential value of using a connected injection device to monitor and study adherence at an international level. It shows that through our validated method of recording adherence with easypod, we can address an unmet need in rhGH therapy, enabling HCPs to accurately identify patients for whom interventions to improve adherence would be beneficial to improve their growth and other clinical outcomes, particularly as the proportion of children with high adherence declined over time, which is consistent with previous findings. The data also show that children who were most adherent to treatment were more likely to transmit their injection data results regularly and have larger catch-up growth than those who were less adherent. This association between adherence and transmission of data may indicate that sharing data with HCPs has a positive impact on adherence rates, and further studies to confirm this are needed. High adherence and transmission rates may reflect the positive use of the system and could be regarded as indirect indicators of usability and utility of the system by patients and HCPs.

Acknowledgments

This study was funded by the healthcare business of Merck KGaA, Darmstadt, Germany (CrossRef Funder ID: 10.13039/1000009945).

The authors would like to thank the patients and their families and the health care professionals who participated in this study. They would also like to thank Dr Ignacio Bergadá of Hospital de Niños Ricardo Güíñez, Buenos Aires, Argentina, for his contribution to the review and interpretation of the data and revision of the manuscript. Medical writing assistance was provided by David Candlish and Amy Evans of inScience Communications, Springer Healthcare Ltd, and funded by the healthcare business of Merck KGaA, Darmstadt, Germany, in accordance with Good Publication Practice (GPP3) guidelines.
Authors' Contributions
AA contributed to review/interpretation of the manuscript. PvD was involved in data analysis, and in data review/interpretation and revision of the manuscript. LA was involved in data collection/analysis and revision of the manuscript. CO contributed to the analysis of the data set and the results of the research project from the perspective of health informatics, evaluation of the evidence for or against the project, and bibliographic review from the perspective of health informatics. LFL was involved in the study design, data interpretation, and revision and review of the manuscript. EK was involved in the concept design, data analysis design, data review/interpretation, and revision of the manuscript. LEC was involved in the design of the study, data review/interpretation, and revision of the manuscript. All authors have approved the final version of the manuscript.

Conflicts of Interest
AA is an employee of Merck SA, Buenos Aires, Argentina (an affiliate of Merck KGaA, Darmstadt, Germany). PvD has a consultancy agreement with the healthcare business of Merck KGaA, Darmstadt, Germany. LA is an employee of Ares Trading SA (an affiliate of Merck KGaA, Darmstadt, Germany). CO does not have any conflicts of interest to declare. LFL is Chief Scientific Officer at Adhera Health Inc, which has a commercial relationship with the healthcare business of Merck KGaA, Darmstadt, Germany. EK is an employee of the healthcare business of Merck KGaA, Darmstadt, Germany, and holds shares in the company. LEC has received honoraria as a lecturer from the healthcare business of Merck KGaA, Darmstadt, Germany, NovoNordisk, and Pfizer.

References


32. Stoyanov G, Koledova E, Vandermeulen J, the Canadian ECOS group. Objectively measured treatment adherence in the easypod connect observational study (ECOS). Canadian interim analysis: population data and case reports. 2016 Presented at: Canadian Pediatric Endocrine Group 2016 Scientific Meeting; February 18-20, 2016; Edmonton, Alberta, Canada.


Abbreviations

ΔHSDS: change in height standard deviation score
ADSS: adherence decision support system
ECOS: Easypod Connect Observational Study
EHR: electronic health record
GH: growth hormone
HCP: health care provider
HSDS: height standard deviation score
PSP: patient support program
rhGH: recombinant human growth hormone

©Aria Assefi, Paula van Dommelen, Lilian Arnaud, Carlos Otero, Luis Fernandez-Luque, Ekaterina Koledova, Luis Eduardo Calliari. Originally published in JMIR mHealth and uHealth (https://mhealth.jmir.org), 20.01.2022. This is an open-access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work, first published in JMIR mHealth and uHealth, is properly cited. The complete bibliographic information, a link to the original publication on https://mhealth.jmir.org/, as well as this copyright and license information must be included.